This Momentum Stock Is Up 1,633% Year-to-Date – Here’s Why It Could Run 5-10x Higher

The company has some very promising COVID-19 solutions in the pipeline that could help shares jump a 5-10x from current levels…

Yulia Kolosova / CC BY

Novavax Inc. (NASDAQ: NVAX) is a biotechnology company headquartered in Maryland that develops vaccines.

The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.

Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.

The company develops product candidates geared toward all age demographics of the general population and believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases.

Since the start of 2020, no stock has performed better than NVAX. It’s up an astounding 1,633% – from $4.50 on Jan. 2nd, to $78 today.

finviz dynamic chart for  NVAX

If you’re worried you missed the rally, don’t. NVAX stock is just heating up…

Novavax has some very promising COVID-19 solutions in the pipeline that could help shares jump an additional 5-10x from here.

While that might sound ambitious, keep in mind the total business is only worth $4.5 billion.

There’s certainly a lot of room to grow. And a $45 billion valuation isn’t outrageous if the company is able to develop a working coronavirus vaccine.

In early May, Novavax was awarded $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) foundation.

And by the end of the month, the company initiated Phase 1/2 of its clinical COVID-19 vaccine trial.

Early results have been promising thus far – which is the main reason why the stock is up more than any other so far this year.

Scientists as Novavax identified its NVX-CoV2373 as its lead SARS-CoV-2 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralizing antibodies.

These results provide strong evidence that the vaccine candidate will be highly immunogenic (able to produce an immune response) in humans, potentially leading to protection from COVID-19 and thus helping to control the spread of the disease.

The full results from Phase 1 are expected in July. When they come in, I’ll be sure to send you an update.

Then, we can focus our attention on Phase 2 and the potential returns that could bring to NVAX stock…

EDITOR'S NOTE: This is the 3rd issue of a 3-part series looking at small-cap stocks. In this edition, we looked at the best small-cap momentum stock. Click here for the best small-cap value stock (part 1), and click here for the best small-cap growth stock (part 2).

$3 EV Play No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$2 Biotech Stock

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only $2.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy

By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works